• Explore /
  • Poster
  • / A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.

A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.

Abstract Poster

Authors

null

Kyriakos P. Papadopoulos

START, San Antonio, TX

Kyriakos P. Papadopoulos, Nehal Lakhani, Melissa Lynne Johnson, Haeseong Park, Ding Wang, Timothy A. Yap, Kathleen N. Moore, Tasha Nicholle Sims, Chetachi A. Emeremni, Maria Karasarides, Glenn S. Kroog

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A

Track

Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT03005782

Citation

J Clin Oncol 37, 2019 (suppl 8; abstr TPS41)

DOI

10.1200/JCO.2019.37.8_suppl.TPS41

Abstract #

TPS41

Poster Bd #

J5

Abstract Disclosures

Similar Posters

First Author: Kyriakos P. Papadopoulos

First Author: Omid Hamid

First Author: Nashat Gabrail

First Author: Judy S. Wang